Advertisement

The International Journal of Cardiac Imaging

, Volume 5, Issue 4, pp 227–231 | Cite as

Is technetium-99 m-pyrophosphate scintigraphy valuable in the diagnosis of cardiac amyloidosis?

  • A. Hartmann
  • J. Frenkel
  • R. Hopf
  • R. P. Baum
  • G. Hör
  • M. Schneider
  • M. Kaltenbach
Article

Abstract

Amyloidosis is a systemic disease frequently involving the myocardium and leading to functional disturbances of the heart. Amyloidosis can mimic other cardiac diseases. A conclusive clinical diagnosis of cardiac involvement can only be made by a combination of different diagnostic methods. In 7 patients with myocardial amyloidosis we used a combined first-pass and static scintigraphy with technetium-99 m-pyrophosphate. There was only insignificant myocardial uptake of the tracer. The first-pass studies however revealed reduced systolic function in 4/7 patients and impaired diastolic function in 6/7 patients. Therefore, although cardiac amyloid could not be demonstrated in the static scintigraphy due to amyloid fibril amount and composition, myocardial functional abnormalities were seen in the first-pass study.

Key words

cardiac amyloidosis cardiomyopathy technetium-99 m-pyrophosphate scintigraphy diastolic function 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cohen AS. Amyloidosis. N Engl J Med 1967; 277: 522–530, 574–583, 628–638.Google Scholar
  2. 2.
    Kyle RA, Greipp PR. Amyloidosis (AL): Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665–683.Google Scholar
  3. 3.
    Brandt K, Cathcart ES, Cohen AS: A clinical analysis of the course and prognosis of forty-two patients with amyloidosis. Am J Med 1968; 44: 955–969.Google Scholar
  4. 4.
    Brigden W. Cardiac amyloidosis. Progr. Cardiovasc Dis 1964; 7: 142–150.Google Scholar
  5. 5.
    Garcia R, Saeed SM. Amyloidosis. Cardiovascular manifestations in five illustrative cases. Arch Int Med 1968; 121: 259–266.Google Scholar
  6. 6.
    Kyle RA, Greipp PR. Amyloidosis (AL): Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665–683.Google Scholar
  7. 7.
    Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: Analysis of 54 necropsy patients. Am J Cardiol 1983; 52: 137–146.Google Scholar
  8. 8.
    Chew C, Ziady GM, Raphael MJ, Oakley CM. The functional defect in amyloid heart disease: the ‘stiff heart’ syndrome. Am J cardiol 1975; 36: 438–444.Google Scholar
  9. 9.
    Hemmingson L, Eriksson P. Cardiac amyloidosis mimicking hypertrophic cardiomyopathy. Acta Med Scand 1986; 219: 421–423.Google Scholar
  10. 10.
    Kuhn H, Mercier J, Köhler E, Frenzel H, Hort W, Loogen F. Differential diagnosis of hypertrophic cardiomyopathies: typical (subaortic) hypertrophic cardiomyopathyl atypical (mild ventricular) hypertrophic cardiomyopathy and hypertrophic non-obstructive cardiomyopathy. Eur H J 4 Suppl 1983; F: 93–104.Google Scholar
  11. 11.
    Meaney E, Shabetai R, Bhargava V, Shearer M, Weidner C, Mangiardi LM, Smalling R, Peterson K. Am J Cardiol 1976; 38: 547–556.Google Scholar
  12. 12.
    Cueto-Garcia L, Tajik AJ, Kyle RA, Edwards WD, Greipp PR, Callahan JA, Shub C, Seward JB. Serial echocardiographicobservations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc 1984; 59: 589–597.Google Scholar
  13. 13.
    Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, Offord KP, Greipp PR, Edwards WD, Tajik AJ. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. Am J Cardiol 1985; 6: 737–743.Google Scholar
  14. 14.
    Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM. Value of positive myocardial technetium-99 m-pyrophosphate scintigraphy in the non-invasive diagnosis of cardiac amyloidosis. Am Heart J 1982; 103: 468–473.Google Scholar
  15. 15.
    Falk RH, Lee VW, Rubinow A, Hood WB, Cohen AS. Sensitivity of technetium-99 m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983; 51: 826–830.Google Scholar
  16. 16.
    Sekiya T, Foster CJ, Isherwood I, Lucas SB, Kahn MK, Miller JP. Computer tomographic appearances of cardiac amyloidosis. Br Heart J 1984; 51: 519–522.Google Scholar
  17. 17.
    Leinonen H, Tötterman KJ, Korppi-Tommola T, Korhola O. Negative myocardial technetium-99 m pyrophosphate scintigraphy in amyloid heart disease associated with type AA systemic amyloidosis. Am J Cardiol 1984; 53: 380–381.Google Scholar
  18. 18.
    Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium-99 m pyrophosphate bone scanning in cardiac amyloidosis. Arch Int Med 1987; 147: 1039–1044.Google Scholar
  19. 19.
    Puchtler H, Sweat F, Levin M. On the binding of Congo red by amyloid. Histochem Cytochem 1962; 10: 355–364.Google Scholar
  20. 20.
    Sivaram CA, Jugduttt BI, Amy RWM, Basualdo LA, Haraphongse M, Shnitka TK. Cardiac amyloidosis: combined use of two-dimensional echocardiography and electrocariography in non-invasive screening before biopsy. Clin Cardiol 1985; 8: 511–518.Google Scholar
  21. 21.
    Carroll JD, Gaasch WH, McAdam KPJW. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982; 49: 9–13.Google Scholar
  22. 22.
    Klepzig H, Standke R, Nickelsen T, Kunkel B, Maul FD, Hör G, Kaltenbach M. Combined first-pass and equilibrium radionuclide ventriculography and comparison with left ventricular/right ventricular stroke count ratio in mitral and aortic regurgitation. Am J Cardiol 1985; 55: 1048–1053.Google Scholar
  23. 23.
    Standke R, Hör G, Maul FD. Fully automated sectorial equilibrium radionuclide ventriculography. Proposal of a method for routine use (exercise and follow up). Eur J Nucl Med 1983; 8: 77–83.Google Scholar
  24. 24.
    Pellikka PA, Homes DR, Edwards WD, Nishimura RA, Tajik AJ. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Int Med 148; 662–666.Google Scholar
  25. 25.
    Swanton RH, Brooksby IAB, Davies MJ, Coltart DJ, Jenkins BS, Webb-Peploe MM. Systolic and diastolic ventricular function in cardiac amyloidosis. Am J cardiol 1977; 39: 658–664.Google Scholar
  26. 26.
    Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BE. Noninvasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross-sectional echocardiography and technetium-99 m pyrophosphate scintigraphy. Br Heart J 1984; 54: 321–326.Google Scholar
  27. 27.
    Hongo M, Hirayama J, Fujii T, Yamada H, Okubo S, Kusama S, Ikeda S. Early identification of amyloid heart disease by technetium-99 m-pyrophosphate scintigraphy: A study with familial amyloid polyneuropathy. Am Heart J 1987; 113: 654–662.Google Scholar
  28. 28.
    Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium-99 m-pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 1987; 147: 1039–1044.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • A. Hartmann
    • 3
  • J. Frenkel
    • 3
  • R. Hopf
    • 3
  • R. P. Baum
    • 1
  • G. Hör
    • 1
  • M. Schneider
    • 2
  • M. Kaltenbach
    • 3
  1. 1.Dept. of Nuclear MedicineFrankfurt University Medical CenterFrankfurt 70West-Germany
  2. 2.Dept. of PathologyFrankfurt University Medical CenterFrankfurt 70West-Germany
  3. 3.Dept. of CardiologyFrankfurt University Medical CenterFrankfurt 70FRG

Personalised recommendations